Background/Aims: Multidrug resistance (MDR) is the most common cause of chemotherapy failure. Upregulation of P-glycoprotein (P-gp) is one of the main mechanisms underlying MDR. Methods: In this study, we developed a targeted drug and small interfering (si)RNA codelivery system based on specific aptamer-conjugated grapefruit-derived nanovectors (GNVs) that we tested in MDR LoVo colon cancer cells. The internalization of nanovectors in cancer cells was tested by fluorescence microscopy and flow cytometry. The anti-cancer activity in vitro was determined by colony formation and cell apoptosis assays. The biodistribution of nanovectors was analyzed by live imaging and the anti-cancer activity in vivo was observed.
Introduction
Multi-drug resistance (MDR) is the major cause of chemotherapy failure. Upregulation of P-glycoprotein (P-gp) expression is one of the main mechanisms underlying MDR [1, 2] . Various strategies have been adopted to overcome MDR in cancer therapy, including monoclonal anti-P-gp antibodies [3] , ATP-binding cassette transporter inhibitors [4] , or targeted knockdown of gene expression using small interfering (si)RNAs [5] . With advances in nanotechnology, an increasing number nanocarrier-based cancer therapeutics have been developed and are being tested in clinical trials for the treatment of drug-resistant cancers [6] [7] [8] . An important benefit of these approaches is that nanocarriers can be internalized by MDR cells via non-specific endocytosis, resulting in higher intracellular accumulation of the drug. To enhance tumor targeting, the nanovector surface is usually modified with a ligand [9] or antibody [10] . Aptamers identified by an in vitro selection procedure known as systematic evolution of ligands by exponential enrichment (SELEX) have broad medical applications as drug delivery ligands due to their low immunogenicity and toxicity, high binding affinity, specificity, and wide range of targets [11, 12] .
In this study, we established a multifunctional co-delivery system based on grapefruit lipid-derived nanovectors (GNVs), which we previously showed to be capable of delivering many types of therapeutic agents including drugs, siRNAs, and antibody without in vivo toxicity [13, 14] . We used the single-stranded (ss)DNA aptamer LA1 specific to MDR LoVo human colon cancer cells (LoVo/MDR cells) to design a LA1/P-gp siRNA (Psi)-conjugated nanocarrier that was loaded with the chemotherapy drug doxorubicin (Dox). LA1 enhanced the targeted delivery of the payload to LoVo/MDR cells, inhibiting proliferation and increasing apoptosis in vitro and suppressing LoVo/MDR cell-derived tumor growth in a mouse xenograft model. This is the first demonstration of a three-pronged approach for the treatment of MDR cancer.
Materials and Methods

Materials
Dox and branched polyethylenimine (PEI; average molecular weight ~25, 000 Da, cat. no. 408727) were purchased from Sigma-Aldrich (St Louis, MO, USA). The near-infrared fluorescein dye DiIC18 (7) (1, 1′-dioctadecyl-3, 3,3′,3′-tetramethylindotricarbocyanine iodide) (DiR) was purchased from Life Technologies (Carlsbad, CA, USA). F-12K medium, fetal bovine serum (FBS), penicillin, and streptomycin for cell culture were obtained from Thermo Fisher Scientific (Waltham, MA, USA).
Cell culture and mice
LoVo human colon cancer cells were purchased from American Type Culture Collection (Manassas, VA, USA). LoVo/MDR cells were generated by exposing the cells to increasing concentrations of Dox. LoVo and LoVo/MDR cell lines were maintained in F-12K medium supplemented with FBS (10%), penicillin (50 IU/ ml), and streptomycin (50 ng/ml) and cultured in a humidified CO 2 incubator at 37°C.
BALB/c and BALB/c SCID mice (6-8 weeks old) were purchased from the Institute of Comparative Medicine of Yangzhou University (Yangzhou, China). Animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Bethesda, MD, USA).
Aptamer selection
The original ssDNA library contained 86-mer oligonucleotides with the sequence 5'-GGATCCTATGACGCATTGACCC-N30-GGCTCGGACTGTTCCCTATAGTGAGTCGTATTAG-3', in which N30 represents random oligonucleotides based on equal incorporation of A, T, G, and C at each position. The procedure for aptamer selection has been previously reported [15] . Briefly, the original ssDNA library was denatured for 5 min at 95°C and cooled for 10 min on ice. After incubation with LoVo/MDR cells on ice for 1 h, the supernatant was removed and cells were collected and resuspended in 500 μl ddH 2 O. Cell-bound ssDNA was harvested by heating for 5 min at 95°C and used as template for PCR amplification. Doublestranded (ds)DNA was used as a template for asymmetric PCR, and the ssDNA products were used in the next round of selection. After three rounds of selection, LoVo cells were used as a negative selection target and unbound ssDNA was incubated with LoVo/MDR cells for the next round of selection. To avoid nonspecific binding in vivo, peripheral blood mononuclear cells (PBMCs) from healthy volunteers were used as a counter selection target after the 10th round of selection. ssDNAs from the 12th round of selection were amplified; dsDNAs were digested and subcloned into the pUC19 vector, which was used to transform Escherichia coli DH5α cells. Selected clones were sequenced and the secondary structure was analyzed using DNAMAN v.3.2 software (Lynnon Biosoft, Pointe-Claire, QC, Canada). Identified aptamers were named LA1…LAn. To examine the uptake of nanovectors with or without loaded LA1 aptamer, GNV-Dox or GNV-Dox-LA1 were incubated with LoVo cells for 6 h at different temperatures (37°C or 4°C) or in culture medium with different pH values (7.4 or 5.5). The cells were collected and washed three times with PBS, and Dox-positive cells were detected by flow cytometry.
Flow cytometry
Preparation and characterization of Dox, LA1, and Psi-loaded GNVs
Free GNVs and GNVs loaded with Dox (GNV-Dox), Dox+LA1 (GNV-Dox-LA1), and Dox+LA1+Psi (GNVDox-Psi-LA1) were prepared as previously reported [16] . Pre-prepared GNV-Dox was incubated with PEI for 60 min at room temperature; after centrifugation at 36, 000 rpm for 1 h, PEI-modified GNV-Dox (GNV-Dox-PEI) were resuspended and incubated overnight at 4°C with LA1 without or with Psi. Free LA1 or Psi was removed by ultracentrifugation at 36, 000 rpm for 1 h.
The average size and zeta potential of GNVs, GNV-Dox, GNV-Dox-LA1, and GNV-Dox-Psi-LA1 were analyzed with the ZLS Z3000 particle sizing system (Nicomp International, Orlando, FL, USA). Nanoparticle morphology was observed with a Nova NanoSEM 230 scanning electron microscope (SEM; FEI Tecnai, Hillsboro, OR, USA).
Florescence microscopy
To determine whether the LA1 aptamer could promote Dox internalized, LoVo/MDR cells were incubated with free Dox, GNV-Dox, and GNV-Dox-LA1 in the wells of a chamber slide at 37°C for 6 h. After three washes with PBS, cells were fixed with 2% paraformaldehyde (PFA) for 10 min at 22°C, and Dox accumulation in the cells was detected by fluorescence microscopy (Leica, Wetzlar, Germany). Total proteins were separated on a 10% polyacrylamide gel by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane that was probed with anti-P-gp or -glyceraldehyde 3-phosphate dehydrogenase (control) antibody. Protein bands were visualized with enhanced chemiluminescence reagent. To visualize P-gp expression in tumor tissues, random biopsies obtained from LoVo cell-derived xenografted tumors were homogenized, lysed, and analyzed by western blotting.
Western blotting
Colony formation assay
Cell proliferation was evaluated with the colony formation assay. Briefly, 200 LoVo/MDR cells were seeded in each well of 6-well plate with 2 ml complete medium. After 24 h, cells were treated with PBS, GNVs, free Dox, GNV-Dox, GNV-Dox-LA1, or GNV-Dox-Psi-LA1 every 5 days for 10 days. The medium was removed and cell colonies were fixed with 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet in PBS for 30 min. The number of colonies was counted and images were obtained with a GelDoc-It2 imager (Bio-Rad, Hercules, CA, USA).
In vivo imaging and biodistribution analysis
Mice were subcutaneously inoculated with LoVo/MDR cells (5 × 10 6 cells per mouse) and then randomly divided into four groups that were intravenously injected with PBS, DiR-GNVs, DiR-GNV-Dox, or DiR-GNV-Dox-LA1. After 24 h, in vivo fluorescence in tumor tissues and major organs (heart, liver, spleen, lung, kidney, brain, and thymus) was imaged with the FX Pro system (Carestream Health, Rochester, NY, USA); signal intensity was quantified using Multiplex software.
To determine the circulation time of nanoparticles, peripheral blood (200 μl) was collected from mice at different time points (24, 48, 72, 96, 120 , and 144 h) and DiR signal intensity was measured with the In vivo FX Pro imaging system.
HE staining
To assess the therapeutic safety, livers and hearts from BALB/c mice treated with PBS or GNV-Dox-LA1 (4 mg/kg Dox, I.V. injection for 1, 3 or 5 times) were fixed overnight in 4% paraformaldehyde and embedded in paraffin; 5 µm sections of tissues were than stained with H&E.
Assessment of liver damage
BALB/c mice were treated with PBS or GNV-Dox-LA1 (4 mg/kg Dox, I.V. injection for 1, 3 or 5 times), the sera of mice was collected 24 h after treatment, the ALT, AST and ALP were quantitatively analyzed using the Clinical Chemistry Analyzer for animals (BS-240 VET, Mindray, China).
LoVo cell-derived xenograft tumors in mice
LoVo/MDR cells were subcutaneously injected into the right fore flank of each SCID mouse. After reaching a volume to ~100 mm 3 , LoVo/MDR cell-derived tumor-bearing mice were randomly divided into six groups (n = 5 mice/group) and were intravenously injected with PBS, GNVs, free Dox (4 mg/kg), GNV-Dox (4 mg/kg Dox), GNV-Dox-LA1 (4 mg/kg Dox), and GNV-Dox-Psi-LA1 (4 mg/kg Dox; 1 mg/kg Psi) every 5 days for a total of five times. Tumor size and weight were recorded after 30 days and P-gp expression in tumors was analyzed by western blotting.
Statistical analysis
Data are expressed as mean ± SD. Differences among groups were compared with the two-tailed Student's t test and by analysis of variance. Differences were considered statistically significant at p< 0.05.
Results
Selection of aptamers recognizing LoVo/MDR cells
Cell-SELEX was carried out to obtain aptamers specific to LoVo/MDR cells (Fig. 1A) . LoVo/MDR cells with lower drug accumulation (Fig. 1B, C) and higher P-gp expression (Fig.  1D) were maintained in our laboratory for use as target cells. After 12 rounds of selection, the ssDNA pool was amplified, subcloned, and sequenced. The top three aptamers (LA1, 36%; LA2, 14%; and LA3, 10%; Fig. 1E ) from among 50 clones were selected while the original ssDNA library served as control aptamer (Fig. 1F) . LA1 bound to LoVo/MDR cells with highest affinity (Fig. 2A, B , Kd=39.6±5.9 nM) and best specificity (Fig. 2C, D , Kd=33.6±4.9 nM). To prevent non-specific binding to normal blood cells in vivo, leukocytes from healthy volunteers were incubated with LA1; the results indicated that there was very low cross reactivity (Fig. 2E) .
Characterization of nanovectors
The morphology of GNVs, GNV-Dox, and GNV-Dox-LA1 was observed by scanning electron microscopy. The diameter of the three nanovectors was about 200 nm (Fig. 3A) . Size and surface charge distribution were analyzed by dynamic light scattering; the average sizes were 135.7, 161.2 and 173.4 nm, respectively (Fig. 3B) and average zeta potentials were -33.3, -30.58, and -37.43 mV, respectively (Fig. 3C) .
Internalization of nanovectors by LoVo/MDR cells
Dox accumulation in LoVo/MDR cells was evaluated by incubating the cells with free Dox, GNV-Dox, and GNV-Dox-LA1. Cells incubated with GNVs with or without LA1 modification showed greater accumulation of Dox than those incubated with free Dox (Fig. 4A, B) . This enhancement of drug uptake in the presence of nanovectors was abolished by pretreatment with DNase (Fig. 4C) . Uptake efficiency was temperature-dependent, although temperature had no effect on GNV-Dox-LA1 uptake (Fig. 4D) . Internalization of GNV-Dox and GNV-Dox-LA1 was unaffected by the pH of the medium (Fig. 4E) .
Biodistribution and therapeutic safety of nanovectors
The biodistribution of nanovectors modified with LA1, LoVo/MDR cell-derived tumorbearing mice intravenously injected with PBS, DiR-GNVs, DiR-GNV-Dox, or DiR-GNV-Dox-LA1 was evaluated by in vivo imagine. The DiR signal was weakly detected in tumors, whereas a strong signal was observed in the liver and spleen following DiR-GNV or DiR-GNV-Dox injection. In contrast, in mice injected with DiR-GNV-Dox-LA1, DiR fluorescence was much higher in the tumor than the DiR-GNV or DiR-GNV-Dox injected mice (Fig. 5A , B, ***p<0.001). Additionally, the circulation time of GNVs or GNV-Dox was markedly reduced by conjugating with LA1 (Fig. 5C) .
To further explore the potential in vivo cytotoxic effects of the GNV-Dox-LA1 system, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) of mice pre-treated with GNV-Dox-LA1 were measured for liver injury. ALT, AST and ALP were not induced due to GNV-Dox-LA1 treatments (Fig. 5D ). Histological analysis of tissues from GNV-Dox-LA1 treated animals (Fig. 5E ) revealed no pathological changes in the hearts or livers when compared with tissues from untreated mice.
Characterization and analysis of in vitro GNV-Dox-Psi-LA1 cytotoxicity
For enhanced anti-cancer activity, we developed GNV-Dox-Psi-LA1 (Fig. 6A) ; with a size distribution of 283.8±84.7 nm (Fig. 6B ) and high internalization efficacy in LoVo/MDR cells (Fig. 6C) . LoVo/MDR cells were incubated with PBS, GNVs, free Dox, GNV-Dox, GNV-Dox-LA1, or GNV-Dox-Psi-LA1; P-gp expression was most effectively inhibited in cells treated with GNV-Dox-Psi-LA1 (Fig. 6D) . We also assessed the anti-cancer activity of GNV-Dox-Psi-LA1 in vitro with the colony formation assay and examined apoptosis by Annexin V/propidium iodide staining and flow cytometry. Colony formation by LoVo/MDR cells was attenuated by GNV-Dox, GNV-Dox-LA1, and especially GNV-Dox-Psi-LA1 (Fig. 6E, *p<0 .05 and ***p<0.001). Moreover, the percentage of apoptotic cells was increased from 14.8% in cells treated with free Dox to 24.3% in the presence of GNV-Dox (Fig. 6F, *p<0 .05 and **p<0.01). The proapoptotic effect of GNV-Dox was enhanced by conjugating LA1 (GNV-Dox-LA1, ~30%) or both LA1 and Psi (GNV-Dox-Psi-LA1, ~41%). In vivo anti-cancer activity To investigate the ability of GNV-Dox-Psi-LA1 to inhibit tumor growth in vivo, LoVo/ MDR cells were implanted into SCID mice. Tumor-bearing mice were then intravenously administered GNVs, Dox, GNV-Dox, GNV-Dox-LA1, or GNV-Dox-Psi-LA1 every 5 days for 30 days (Fig. 7A) . GNV-Dox-Psi-LA1 most potently suppressed tumor growth (Fig. 7B , C, **p<0.01 and ***p<0.001) and P-gp expression (Fig. 7D ) in tumors.
Discussion
Nanoparticle-based drug delivery has been used extensively to overcome MDR in cancer. The passive targeting of nanomaterials was the principal advantage in earlier studies. On the one hand, drug solubility and stability can be improved and the circulation time can be prolonged by conjugation with nanovectors, which can also induce the selective transport of drugs to tumor sites based on the enhanced permeability and retention effect [17, 18] . Numerous inorganic [19, 20] and organic nanocarriers [21, 22] have been developed for drug delivery, but their potential hazards to human health and the environment have greatly limited their widespread clinical application [23, 24] . In the present study we modified biocompatible GNVs that were previously developed by our group. Unlike engineered nanoparticles, the GNVs-which were assembled from edible grapefruit-derived lipidshad no detectable toxicity in vitro or in vivo [14] .
Attaching ligands such as folic acid [25] , transferrin [26] , engineered antibodies [27] , or aptamers [28] to the nanoparticle surface can enhance their biocompatibility, uptake, and retention. Aptamer-nanoparticle conjugates are particularly useful for therapeutic applications due to the ability of aptamers to bind with high affinity to a specific target. We initially developed a GNVs modified with LoVo/MDR cell-specific ssDNA aptamers and loaded with Dox (GNVs-Dox-LA1). The presence of LA1 significantly increased Dox internalization in LoVo/MDR cells; the fact that DNase pre-treatment abolished this effect confirmed the role of LA1 in this process. In addition, in contrast to our previous study, we found here that ambient temperature had no effect on GNV-Dox-LA1 uptake by LoVo/MDR cells, indicating that aptamer/target cell binding is ATP independent. Additionally, Dox delivery to LoVo/ MDR tumor tissues was increased by modification of GNV-Dox with LA1, consistent with findings reported by others [29, 30] . 
